Orbimed Genesis Gp Llc
Director at ADARx Pharmaceuticals, Inc. (ADRX); Director at Braveheart Bio, Inc. (BRVE); Director at Prelude Therapeutics Inc (PRLD)
Purchase track record
Not enough history. Based on 1 purchase with a full 90 days of price history.
—
Avg. 90-day return-10.8%
vs. S&P 500-16.6%
Beat the market0%
Paper profit on buys+$3.1M
Total bought / sold$63.6M / $0
Reported trades
| Filed | Stock | Type | Shares | Price | Value | Since |
|---|---|---|---|---|---|---|
| Sep 30SEC | ADRXADARx Pharmaceuticals, Inc. | Buy | 300,24914,325,529 held (+2%) | $17.00 | $5.1M | +4.6% |
| Sep 30SEC | ADRXADARx Pharmaceuticals, Inc. | Buy | 61,5169,292,025 held (+1%) | $17.00 | $1.0M | +4.6% |
| Sep 30SEC | ADRXADARx Pharmaceuticals, Inc. | Buy | 588,235new position | $17.00 | $10.0M | +4.6% |
| Aug 11SEC | BRVEBraveheart Bio, Inc. | Buy | 1,666,66711,901,826 held (+16%) | $18.00 | $30.0M | +11.2% |
| Aug 11SEC | BRVEBraveheart Bio, Inc. | Buy | 273,333new position | $18.00 | $4.9M | +11.2% |
| Apr 23SEC | PRLDPrelude Therapeutics Inc | Buy | 1,689,18911,808,945 held (+17%) | $4.44 | $7.5M | -12.4% |
| Apr 23SEC | PRLDPrelude Therapeutics Inc | Buy | 1,126,126new position | $4.44 | $5.0M | -12.4% |
- Buy
Director Orbimed Genesis Gp Llc bought $10.0M of ADRX at $17.00 — first open-market purchase in our records; opens a new position.
- Buy
Director Orbimed Genesis Gp Llc bought $30.0M of BRVE at $18.00 — first open-market purchase in our records.
- Buy
Director Orbimed Genesis Gp Llc bought $4.9M of BRVE at $18.00 — opens a new position.
- Buy
Director Orbimed Genesis Gp Llc bought $7.5M of PRLD at $4.44 — first open-market purchase in our records.
- Buy
Director Orbimed Genesis Gp Llc bought $5.0M of PRLD at $4.44 — opens a new position.